Insights Blog

UK biotech M&A reveals Big Pharma’s shift from risky early-stage bets to premium-priced, revenue-ready acquisitions as the patent cliff looms.

A pragmatic, post-JPM and post-ATW look at the state of cell therapy development, from LVV design to CMC realities and scientific decision-making.

As focus shifts from lifespan to health span, a real question emerges: will value remain fragmented across well-capitalized point solutions, or concentrate in a handful of platforms that specialize in personalizing medicine across women’s life stages?

A Q&A with Matt Marlowe on China’s evolving sequencing landscape — and what it means for Illumina.

A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides updated insight into how genomics technologies are being evaluated, adopted, and used across Europe’s solid tumor oncology markets.

New updates in the digital health landscape!